Results 131 to 140 of about 58,665 (272)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease. [PDF]

Curr Neuropharmacol, 2023
Jing XZ, Yang HJ, Taximaimaiti R, Wang XP.   +3 more
europepmc   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. [PDF]

Front Endocrinol (Lausanne), 2021
Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS.   +6 more
europepmc   +1 more source

Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats [PDF]

, 2014
Michael Ezrokhi, Shuqin Luo, Yelena Trubitsyna, Anthony H. Cincotta   +3 more
openalex   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Dopamine agonists for preventing ovarian hyperstimulation syndrome. [PDF]

Cochrane Database Syst Rev, 2021
Tang H, Mourad SM, Wang A, Zhai SD, Hart RJ.   +4 more
europepmc   +1 more source

The dopamine D2/D3 receptor agonist quinpirole increases checking-like behaviour in an operant observing response task with uncertain reinforcement: A novel possible model of OCD [PDF]

, 2014
Dawn M. Eagle, Cristie Noschang, Laure-Sophie Camilla d’Angelo, C Noble, Jacob Day, Marie Louise Dongelmans, David Theobald, Adam C. Mar, Gonzalo P. Urcelay, Sharon Morein‐Zamir, Trevor W. Robbins   +10 more
openalex   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas. [PDF]

Acta Endocrinol (Buchar), 2021
Capatina C, Poiana C.
europepmc   +1 more source